Kornimate/medical-research-clean huggingface dataset:
intra-articular analgesia versus adductor canal block for arthroscopic knee surgery

Conditions: Post-Operative Pain, Chronic

Summary: this study is a randomized study that compares two commonly used post-operative pain reducing techniques by measuring the level of pain and use of pain medication after knee surgery.

post-operative pain is a commonly associated with knee surgery. treatment often includes an oral or intravenous (iv) narcotic regimen which often leads to nausea, vomiting and can cause consti-pation. these issues can contribute to the overall discomfort of the post-operative patient. intra-operative injections and local nerve blocks have become common adjuncts to narcotics to reduce post-operative pain and the necessity for oral or iv narcotic use. the aim of this study is to com-pare analgesic use and clinical effects on post-operative pain management with intra-articular in-jection of 20ccs of 2% lidocaine with epinephrine at the start of the case plus 20ccs 0.5% mar-caine with epinephrine at the end of the case vs. adductor canal saphenous nerve blockade in pa-tients undergoing knee arthroscopy, as indicated by the need for rescue narcotics and patient pain scores. a randomized, single blinded study will be performed to evaluate post-operative pain control using vas scores at 1, 2, 4, 8, 12, 24, 36, and 48hrs post-operatively, rescue narcotic use in the pacu, and total narcotic consumption over the same time period.

Eligibility criteria:
inclusion criteria: * asa i-iii patients * age 18 to 65 years exclusion criteria: * allergy or intolerance to local anesthetics, nsaids, or opioids * inability to understand the consent or study process * any contraindication to regional anesthesia * known history of substance abuse * chronic home opioid therapy * history of major neurologic deficit in operative limb * chronic pain syndromes * pregnancy and nursing women
study of the role of pcsk9 and fxr in the physiopathology of the joint dyslipidemia associated to the human immunoresistance

Conditions: Obesity

Summary: experimental results are strongly suggesting that pcsk9 and fxr could occur in the physiopathology of human joined dyslipidemia. but no data in the literature can validate the potential role of these two genes in the lipidic and glucidic metabolism control in physiopathological situations. this protocol is based on the hypothesis that the expression levels of pcsk 9 and fxr are modified for some patients suffering from insulin resistance and dyslipidemia.


Eligibility criteria:
inclusion criteria: * corporal mass index \> 40 kg/m² or \> 35 kg/m² associated to a co-morbidity resistant to a diet * bariatric surgery planned * no lipid-lowering drugs during 4 weeks before surgery * no treatment by metformin during 4 weeks before surgery * no treatment by glitazones during 8 weeks before surgery * age of the patient between 18 and 65 years * consent form signed * patient with social insurance exclusion criteria: * age inferior to 18 years * women pregnant * coagulation troubles * surgery contraindicated * chronic hepatitis b or c active * vih infected * other chronic hepatic disease * patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a cardiovascular pathology * type 2 diabetes under insulinosensitivator treatments

Keywords: bariatric surgery planned
panlar's latin american registry of rheumatic patients treated with jak inhibitors

Conditions: Arthritis, Rheumatoid; Arthritis, Psoriatic; Spondyloarthritis

Summary: this prospective, non-interventional, research registry is designed to study the comparative safety and comparative effectiveness of approved jak inhibitors treatment for ra-psa-spa in a cohort of patients and theirs controls cared for by rheumatologists across latin américa (la).

there is scarce data on the real-world safety and effectiveness of jak in latin america. this registry will provide reliable data on the use of jaki in la, as will be a prospective study involving carefully selected rheumatologists and centers. soon, a good number of copies of original jaki will be available in la, and it is important to keep track of the safety and effectiveness of this drugs in the real world. the primary objective of the registry is to prospectively study the comparative safety and comparative effectiveness of approved jak inhibitors treatment for ra-psa-spa in a cohort of patients and theirs controls cared for by rheumatologists across latin américa (la). the registry will be a cohort study where cases will be patients with ra, psa and spa initiating any approved jak inhibitor. to have an active control group, patients with ra, psa o spa initiating any other disease modifying antirheumatic drug (dmard) (biologic or not biologic) will also be included in the registry. it will be a web based registry, where the investigators will include data related to the cases and controls. data collected will include, demographics, disease characteristics, disease activity, past and current medications, comorbidities. at each visit adherence with the medications, adverse events, changes in medications, disease activity and disability will be assessed.patients will be followed up at three months intervals, after inclusion in the registry and thereafter every 6 months during the next three years. adverse events could be included at any time between visits if the investigator is notified.

Eligibility criteria:
to be eligible for enrollment into the prejak registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below. inclusion criteria the patient must be: 1. one of the following: 1. diagnosis with rheumatoid arthritis (ra) and initiating (prescribed or starting) a januse kinase inhibitors (jaki) for the treatment of ra at the enrollment visit. 2. meet the asas criteria for axial spondyloarthritis (axspa), including radiographic or non-radiographic, and initiating (prescribe or starting) a jaki for the treatment of axspa at the enrollment visit. 3. diagnosis with psoriatic arthritis (psa) and initiating (prescribed or starting) a januse kinase inhibitors (jaki) for the treatment of psa at the enrollment visit. 2. at least 18 years age or older 3. able and willing to provide written consent exclusion criteria: patients who do not wish to participate or are unable to give informed consent

Keywords: rheumatoid arthritis psoriatic arthritis spondyloarthritis janus kinase inhibitors
counseling during pulmonary rehabilitation

Conditions: COPD

Summary: the purpose of this study is to investigate if a physical activity counseling program during pulmonary rehabilitation increases the physical activity level in daily life in patients with chronic obstructive pulmonary disease.

participants performed a 12 weeks outpatient pulmonary rehab (pr) according to guidelines. participants allocated to intervention received pr plus physical activity (pa) counselling. pa counselling was performed using "motivational interviewing" techniques and was provided by two experiences physiotherapists independant to the rehab team. after pr and three months follow-up was evaluated if pa counselling during pr increases pa elvel (primary outcome: steps per day) in daily life. furthermore, individual, semi-structured interviews were performed in a subgroup of participants in order to gain more detailed information about barriers and enablers of participation in daily-life activities. participants were invited to two interviews, one right after pr the other after 3 months follow up. a content analysis was performed.

Eligibility criteria:
inclusion criteria: * confirmed copd (gold stages b-d) according to gold-guidelines exclusion criteria: * mental or physical disability (mini-mental score \<20) precluding informed consent or compliance with the protocol * morphine medication * primary diagnosis of heart failure * uncontrolled arrhythmias causing symptoms or hemodynamic compromise * severe co-morbidity (acute coronary syndrome, unstable angina terminal renal failure, concomitant pulmonary embolism, very severe pneumonia: curb65\>3) * severe untreated arterial hypertension at rest (\> 200 mm hg systolic, \> 120 mm hg diastolic)
platelet rich fibrin on root coverage of gingival recessions

Conditions: Gingival Recession

Summary: several surgical techniques and various adjunctive agents have been used to covered gingival recession (gr) and promote clinical outcomes. the treatment of the gr more used (gold standard) is the root coverage with surgical procedures and connective tissue graft, but it has limitations due to the conditions of the donor graft. is necessary develop other biomaterials for these cases. the platelet rich fibrin is a autologous biomaterial that has gained tremendous momentum having been utilized for a variety of dental and medical procedures including periodontal surgeries. however, results remain contradictory and mainly focus on the hard and soft tissue healing, aesthetics and postoperative discomfort. the objective of this study was to evaluate the clinical effects of coronal advanced flap (caf) and caf + platelet rich fibrin (prf) on root coverage (rc) over a period of 24 month.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * healthy males and females of age 18-60 years old * multiple bilateral (maxillary or mandibular) gingival recessions (miller class і or ii) * good oral hygiene (o´leary index ≤ 15%) exclusion criteria: * active periodontal disease * periodontal surgeries in the last three years * pregnancy or lactation * smokers or alcoholics * platelet dysfunction syndrome or thrombocytopenia * coagulation defects * uncontrolled diabetes * medical contraindications to elective oral surgery procedures * severe immunodeficiencies * oncological history * prosthetic restorations adjacent to gingival recessions * mobility ii or iii * occlusal contacts excessive * root caries * buccal restaurations class v

Keywords: platelet-rich fibrin platelet concentrates periodontal diseases
evaluation of correlation between oculometric measures and clinical assessment in parkinson's disease

Conditions: Parkinson Disease

Summary: this is a multicenter longitudinal study in about 300 patients with idiopathic parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. this study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.

this is an multicenter longitudinal study, in about 300 patients with idiopathic pd in several centers. the aim of this study is to evaluate the correlations between oculometric measures and clinical assessment, e.g. the movement disorder society-sponsored revision of the unified parkinson's disease rating scale (mds-updrs) and the moca score over time ,in subjects who meet the inclusion and exclusion criteria, and who provide a signed informed consent. in addition, the investigators aim to demonstrate that oculometric measures are able to detect patient deterioration faster than can be detected using the currently available clinical assessment tools. all patients will be assessed over a period of 12 months (5 assessments, at 0, 3, 6, 9, 12 months). during this time period, every subject who consents will undergo a neuralight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye- tracking system (tobii, ce-marked class b approved device) (approx. 30 minutes). the oculometric evaluation will occur for every patient every 3 months. all assessments will be performed during a clinic visit unless authorized to be conducted remotely. during the study, the sponsor will be blinded to the private details of the subjects.

Eligibility criteria:
inclusion criteria: * men and women with idiopathic pd (hoehn \& yahr scale 1-2) * age between 40 and 85 years old * 0 to 5 years' time since diagnosis * normal or corrected vision * ability to follow instructions * willing and able to sign an informed consent form * no anticipated changes in pd medications from baseline throughout the study duration based on clinical status during screening * if treated, stable on treatment for at least 3 months exclusion criteria: * inability to sit for 40 minutes on a chair in a calm manner * personal or 1st degree relative history of epilepsy * additional neurological diseases * drug or alcohol abuse (except for using medical cannabis during 24 hours prior nl examination date) * pregnancy or a potential pregnancy (self-declaration)
study evaluating cmc-544 in b-cell non-hodgkin's lymphoma

Conditions: Lymphoma, B-Cell

Summary: to determine the maximum tolerated dose (mtd), the tolerability, and the initial safety profile of cmc-544 in subjects with b-cell non-hodgkin's lymphoma (nhl).


Eligibility criteria:
inclusion criteria: * subjects who have been previously diagnosed with cd22-positive, b-cell nhl, according to who classification, which has progressed after at least 2 prior therapies of probable clinical benefit * at the expanded cohort, part 2 of the study, subjects must have one of the following: * follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy * diffuse large b-cell lymphoma * age 18 years or older exclusion criteria: * candidate for potentially curative therapies in the opinion of the investigator * chronic lymphocytic leukemia * burkitt's lymphoma, primary effusion lymphoma, and precursor b-cell lymphoblastic lymphoma

Keywords: b-cell non-hodgkin's lymphoma
dry needling versus instrumented assisted soft tissue mobilization in the patient with cervicogenic treatment headache

Conditions: Cervicogenic Headache

Summary: the aim of this study is to investigate the efficacy of dry needling versus instrumented assisted soft tissue mobilization in the patient with cervicogenic treatment headache

cervicogenic headache has been classified as a secondary type headache, and it is usually associated with cervical myofascial pain sources as myofascial trigger points . it also could be related to any joint, disc, and ligament disease of the upper region of the neck.physiotherapist use trigger point dry needling as an invasive treatment for cgh where a solid filament needle is inserted into a myofascial trigger point . the advantages of dry needling are increasingly documented .instrument-assisted soft tissue mobilization technique has been reported to decrease pain, improve overall function, and increase range of motion . it enhances the ability of physical therapists to detect altered tissue properties, through the vibration sense within the instrument, and to treat soft tissue dysfunction. it also enhances the patient's awareness of altered sensations within the treated tissues.

Eligibility criteria:
inclusion criteria: * 20 to 60 years old patient with unilaterally of the head pain * pain triggered by external pressure over the upper cervical joints (c1-c3) * pain elicited by the neck movements, and/or sustained awkward positions with reduced neck rom * headache intensity pain score of at least 20mm on the visual analogue scale (vas) * headache frequency of at least once a week for at least 3 months * minimum neck disability index score of 10 points or greater exclusion criteria: * migraine, tension- type headache, tumor, osteoporosis, fracture, rheumatoid arthritis and metabolic diseases. * prolonged history of steroid use. * resting blood pressure greater than 140/90 mmhg. * cervical spinal stenosis, diminished sensation and central nervous system involvement, * previous head or neck surgery or whiplash injury history within the last 6 weeks

Keywords: dry needling cervicogenic headache instrumented assisted soft tissue mobilization
idh1/2 mutational analysis in aml patients: diagnosis and follow-up

Conditions: Acute Myeloid Leukemia

Summary: in a spanish series of aml patients it is intended to perform, at the moment of diagnosis, pyrosequencing of idh1 and idh2 genes. taking into account the incidence of aml in the area, it is planed to study 100 patients per year. among the cases with idh1/2 mutations, targeted deep sequencing (tds) of a panel covering coding regions of 40 myeloid related genes will be applied. with tds, pyrosequencing results will be validated at the same time that prognosis value of co-mutated genes could be studied. furthermore, with tds, molecular architecture of idh1 and idh2 mutated cases might be better understood.


Eligibility criteria:
inclusion criteria: * patients \>18 years old with de novo acute myeloid leukemia will be included. all patients will be treated according to clinical routine. exclusion criteria: * patients not following the above criteria.
the cost of obsessive-compulsive disorder (ocd) in china

Conditions: Obsessive-Compulsive Disorder

Summary: the purpose of this study is to estimate the cost of obsessive-compulsive disorder in china based on the prevalence rate from a social perspective.

obsessive-compulsive disorder(ocd) is one of relatively common mental disorders with a prevalence of 1.63% in china. ocd usually begins in adolescence or young adulthood , it will become a chronic disabling disease, if it is not treated in timeand.ocd can be so severe that it can seriously impact on some or all areas of a person's life, bring huge economic burden. at present, there is only one article on the cost of ocd in the united states in the 1990s, and this part of the data in china is blank.a cross-sectional study recruited 600 patients with ocd from 13 hospitals in eastern, western, southern, and northern china. a structured questionnaire was used for face-to-face interviewing to collect costs related to ocd. the direct costs for each patient and indirect costs ffor each patient and their caregivers were calculated . the human capital method is used to calculate indirect costs. through weighting, the cost of ocd in china is estimated from a social perspective using a bottom-up methodology.

Eligibility criteria:
inclusion criteria: * primarily diagnosed ocd meet dsm-5 critera * 16-65 years old * get informed consent from patients exclusion criteria: * concurrent neuropsychiatric diseases such as schizophrenia, which severely interfere with treatment costs * drug abuser * unable to understand the questionnaire
mental imagery enhances proprioception in patients with low back pain

Conditions: Low Back Pain

Summary: mental imagery has been used in a variety of pathological instances in support to classical therapeutic treatments. the aim of the present study was to observe the effect of internal kinesthetic and external visual imagery to improve proprioceptive feedback in low back pain. fifty-five subjects with a history of low back pain were included in two experimental groups who used mental imagery and one control group who did not. the results showed the effectiveness of the internal kinesthetic imagery to improve the accuracy of repositioning of lumbo-sacral spine that may subsequently improve the quality of the proprioceptive input. the possibility to use effectively mental imagery, as a part of proprioceptive rehabilitation process, is the principal outcome of this study.


Eligibility criteria:
inclusion criteria: * subjects suffering from common non-specific low back pain exclusion criteria: * recent history of inner ear infection causing associated balance or coordination problems * history of cerebral trauma followed by unresolved neurosensory symptoms * recent history of vestibular disorder and previous spinal surgery * an involvement in specific balance or stabilization training during the 6 months prior testing. patients taking pain medication were excluded from the study.

Keywords: improvement of the accuracy of lumbar repositioning
prospective safety and tolerability assessment of a cardiovascular health dietary supplement

Conditions: Hypertension

Summary: this single-arm, open-label study will assess the safety and tolerability of one daily tablet of a commercially available cardiovascular health dietary supplement by questionnaire and blood markers in adults with borderline to mild hypertension over a 6 month period. although the cardiovascular health dietary supplement being investigated has been on the market for over 20 years, prospective safety data and blood markers of end organ function have not previously been reported.

hypertension is an important overall risk factor for developing cardiovascular disease in the united states, and is a leading risk factor for cardiovascular events, including myocardial infarction and stroke, and cardiovascular-related mortality with advancing age. based on population based studies and clinical trials, both systolic blood pressure (sbp) and diastolic blood pressure (dbp) elevations are continuous, strong and independent risk factors for cardiovascular disease. the product being studies is a cardiovascular health dietary supplement that has been commercially available since 1993. it is currently sold to healthcare practitioners as well as directly to consumers. some healthcare providers use the product as part of a plan to treat high blood pressure in their patients. this is the first study collecting prospective safety data on this product.

Eligibility criteria:
inclusion criteria: * age 18-65 * systolic blood pressure 120-159 mmhg or diastolic blood pressure 80-99 mmhg upon screening exclusion criteria: * bradycardia * initiation of or changes to blood pressure lowering medications within the last month * initiation of or changes to thyroid medications within the last month * currently taking any of the following orally (or they were taken within the last month): * rauwolfia serpentina, terminalia arjuna, tribulus terrestris, convolvulus pluricaulis, boerhavia diffusa, rosa vinca, rose powder, or coral powder * beta blockers * alpha blockers * propranolol * digoxin * levodopa * anti-depressant medications * anti-psychotic medications * sedatives or tranquilizers * present or past history of any of the following: * cardiovascular disease * heart surgery * cardiac arrhythmia * abnormal ekg * abnormal echocardiogram * diabetes * chronic liver, kidney or bowel disease * ulcers * gallbladder disease * depression * alcoholism * obstructive sleep apnea and/or use of a continuous positive airway pressure device * parkinson's disease * pheochromocytoma * cancer within the last 5 years * consuming more than fourteen alcoholic beverages per week * current smoking/tobacco use * current illicit and/or recreational drug use * women who are lactating, pregnant or planning pregnancy within the next six months * known intolerance or allergy to study agents